Baylor Scott & White transplant team performs its 21st robotic living donor hepatectomy

Living liver donors report an immense emotional and spiritual benefit from knowing they are saving the life of a loved one. However, it is impossible to overlook the surgical trauma, cosmetic scars and surgical risks to which otherwise healthy donors are exposed with this major operation. To mitigate the potential harm to donors, Baylor Scott & White Annette C. and Harold C. Simmons Transplant Institute has begun performing robotic living donor hepatectomies, one of only two programs in the United States to do so. The transplant team recently performed its 21st robotic living donor hepatectomy.

Read more

Baylor Scott & White takes lead on improving liver health

The burden of liver disease is increasing in Dallas/Fort Worth and throughout the nation. In addition to alcohol abuse or misuse, there has been an alarming increase in the incidence of non-alcoholic fatty liver disease, a leading cause of cirrhosis.    

Read more

ECMO Reunion celebrates survivors and families

The extracorporeal membrane oxygenation (ECMO) program at Baylor Scott & White All Saints Medical Center – Fort Worth celebrated survivorship with joy, hope and fellowship at the ECMO Reunion on January 6. The event brought together ECMO patients and families from all over Texas to reunite with the physicians and staff members who made recovery possible.

Read more

Center offers proactive approach to heart failure management

Since 2019, the Advanced Heart and Lung Disease Center at Baylor Scott & White All Saints Medical Center – Fort Worth has offered a specialized approach to managing patients with heart failure. While the center provides options for heart failure in its most advanced stage, it also focuses on preventing the progression of the condition.

Read more

AIM HIGHer evaluates CCM in heart failure patients with higher EF

Baylor Scott & White Heart and Vascular Hospital – Fort Worth is actively recruiting for a study of cardiac contractility modulation (CCM) in a new group of heart failure patients. The AIM HIGHer study will evaluate the efficacy and safety of implantable CCM therapy in those with symptomatic heart failure and an ejection fraction (EF) between 40 and 60%.

Read more